Publication
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (11)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 11
- cancerCutaneous Melanomacivic_curation1.00
- drugCarboplatincivic_curation1.00
- drugDocetaxelcivic_curation1.00
- drugPaclitaxelcivic_curation1.00
- drugSorafenibcivic_curation1.00
- geneCCND1civic_curation1.00
- geneKRAScivic_curation1.00
- geneRAF1civic_curation1.00
- variantCCND1 Amplificationcivic_curation1.00
- variantKRAS Amplificationcivic_curation1.00
- variantRAF1 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26307133
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CCND1 Amplification1 | ||||||||
| Carboplatin + Paclitaxel + SorafenibCombination | Cutaneous MelanomaALIAS | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID1495Retrospective analysis of somatic mutations and copy number changes in 119 patient treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved … (full text at CIViC) PMID 26307133 · Wilson et al., 2016 · Open in CIViC | civic |
| KRAS Amplification1 | ||||||||
| Carboplatin + Docetaxel + SorafenibCombination | Cutaneous MelanomaALIAS | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID1497Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved… (full text at CIViC) PMID 26307133 · Wilson et al., 2016 · Open in CIViC | civic |
| RAF1 Amplification1 | ||||||||
| Carboplatin + Paclitaxel + SorafenibCombination | Cutaneous MelanomaALIAS | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID1496Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved… (full text at CIViC) PMID 26307133 · Wilson et al., 2016 · Open in CIViC | civic |